Actinium Pharmaceuticals, a
New York-based biopharmaceutical company focusing on development of innovative
immunotherapeutic solutions for advanced cancers treatment, today announced it
will be presenting at the Biotech Showcase 2014 Conference. The conference will
be taking place January 13-15, 2014 at the Wyndham Hotel in San Francisco
California.
Dr. Kaushik J. Dave,
President and CEO of Actinium Pharmaceuticals, will be giving a corporate
update on Monday, January 13, 2014, at 4:30 PM PST (Pacific Time) in the
Mission II Room of the hotel. A webcast of the presentation will be available
as well.
For watching the
presentation, onlookers are advised to use the following link:
http://www.media-server.com/m/p/qbc4c7nh
Actinium Pharmaceuticals is
focusing on developing alpha particle radioimmunoconjugates for advanced
cancers treatment. The company’s targeted radiotherapy is based upon its
proprietary platform for tapping into the power of alpha-emitting actinium-225
and bismuth-213 and specific beta-emitting radiopharmaceuticals in conjunction
with monoclonal antibodies for cancer treatment. The company’s primary
radiopharmaceutical, Iomab(TM)-B, will be utilized for patient preparation for
bone marrow transplants. It is currently being tested in a Phase III clinical
study in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the
age of 55. The company’s secondary program, Actimab-A, is currently in clinical
development.
For more information, visit:
www.actiniumpharmaceuticals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
